Sangamo Therapeutics (SGMO) News Today → Gold Mania (From Stansberry Research) (Ad) Free SGMO Stock Alerts $0.56 +0.03 (+5.71%) (As of 05/3/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineSangamo Therapeutics (SGMO) Scheduled to Post Quarterly Earnings on Thursdaymarketbeat.com - May 3 at 9:16 AMSangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcastbusinesswire.com - May 2 at 4:15 PMSangamo Therapeutics Inc.wsj.com - April 30 at 2:40 AMHead to Head Survey: Compass Therapeutics (NASDAQ:CMPX) vs. Sangamo Therapeutics (NASDAQ:SGMO)americanbankingnews.com - April 30 at 1:38 AMSangamo Therapeutics (NASDAQ:SGMO) Research Coverage Started at StockNews.comamericanbankingnews.com - April 27 at 2:18 AMSangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Consensus Recommendation of "Hold" by Brokeragesmarketbeat.com - April 23 at 4:26 AMSangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)businesswire.com - April 22 at 4:35 PMStock Traders Purchase Large Volume of Sangamo Therapeutics Call Options (NASDAQ:SGMO)marketbeat.com - April 22 at 11:38 AMBiotech Roundtable: Who will bring the next CRISPR drug to market?msn.com - April 2 at 11:56 AMSangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Consensus Recommendation of "Hold" from Brokeragesmarketbeat.com - March 29 at 4:26 AMSangamo Therapeutics (NASDAQ:SGMO) Share Price Passes Above 200-Day Moving Average of $0.62marketbeat.com - March 29 at 2:31 AMWhat You Need To Know About The Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Analyst Downgrade Todayfinance.yahoo.com - March 25 at 10:26 PMQ1 2024 Earnings Estimate for Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Issued By HC Wainwrightmarketbeat.com - March 21 at 8:02 AMSangamo Therapeutics Incmoney.usnews.com - March 19 at 6:57 PMSangamo Therapeutics (NASDAQ:SGMO) Given "Buy" Rating at HC Wainwrightmarketbeat.com - March 19 at 8:34 AMSangamo Therapeutics' (SGMO) Sector Perform Rating Reaffirmed at Royal Bank of Canadamarketbeat.com - March 18 at 5:11 PMQ1 2024 Earnings Estimate for Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Issued By Wedbushmarketbeat.com - March 18 at 1:27 AMSGMO Apr 2024 1.500 putca.finance.yahoo.com - March 16 at 11:33 PMAnalysts Conflicted on These Healthcare Names: Veradigm (OtherMDRX), ADC Therapeutics (ADCT) and Sangamo Biosciences (SGMO)markets.businessinsider.com - March 16 at 8:32 AMSGMO Apr 2024 1.500 callfinance.yahoo.com - March 16 at 3:31 AMSGMO Apr 2024 3.000 callfinance.yahoo.com - March 15 at 10:29 PMSangamo Therapeutics Full Year 2023 Earnings: Misses Expectationsfinance.yahoo.com - March 14 at 4:24 PMSangamo Biosciences’ Breakthrough Capsid Technology Spurs Buy Ratingmarkets.businessinsider.com - March 13 at 8:10 PM4 Analysts Assess Sangamo Therapeutics: What You Need To Knowmarkets.businessinsider.com - March 13 at 8:10 PMSangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Resultsbusinesswire.com - March 13 at 8:05 AMSangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcastbusinesswire.com - March 12 at 6:30 PMSangamo Therapeutics, Inc. (SGMO)finance.yahoo.com - March 1 at 9:22 AMSangamo Therapeutics (SGMO) Earnings Dates & Reportsinvesting.com - February 23 at 7:58 PMSangamo Therapeutics, Inc. (NASDAQ:SGMO) Sees Significant Growth in Short Interestmarketbeat.com - February 17 at 3:10 AMSangamo Biosciences: Hold Rating Amid Regulatory Progress and Financial Uncertaintiesmarkets.businessinsider.com - February 13 at 1:56 PMSangamo Therapeutics' (SGMO) "Buy" Rating Reiterated at HC Wainwrightmarketbeat.com - February 12 at 1:58 PMSangamo Therapeutics Reports U.S. And European Regulatory Support For ST-920markets.businessinsider.com - February 12 at 12:54 PMWith 55% ownership of the shares, Sangamo Therapeutics, Inc. (NASDAQ:SGMO) is heavily dominated by institutional ownersfinance.yahoo.com - February 12 at 12:54 PMSangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Diseasefinance.yahoo.com - February 12 at 12:54 PMSangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Consensus Recommendation of "Hold" by Analystsmarketbeat.com - February 8 at 3:35 AMSangamo’s STAAR Study Shows Promise in Fabry Disease Treatmentmsn.com - February 7 at 6:47 PMSangamo Therapeutics (NASDAQ:SGMO) Rating Reiterated by HC Wainwrightmarketbeat.com - February 6 at 9:06 AMSangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profilefinance.yahoo.com - February 5 at 9:44 PMDeep Dive Into Sangamo Therapeutics Stock: Analyst Perspectives (4 Ratings)markets.businessinsider.com - January 19 at 3:26 PMBay Area biotech Sangamo puts entire Peninsula headquarters up for subleasebizjournals.com - January 16 at 6:19 PM2 low-priced gene therapy stocks to speculate on (SGMO)marketbeat.com - January 8 at 8:26 AMSangamo Therapeutics Stock (NASDAQ:SGMO) Insider Tradesbenzinga.com - November 30 at 12:22 PMTruist Securities Downgrades Sangamo Therapeutics (SGMO)msn.com - November 8 at 2:07 AMWells Fargo Downgrades Sangamo Therapeutics (SGMO)msn.com - November 6 at 10:55 PMWells Fargo downgrades Sangamo, cites removal of key year-end catalystmsn.com - November 6 at 5:54 PMWhere Sangamo Therapeutics Stands With Analystsmarkets.businessinsider.com - November 6 at 5:54 PMWhat 8 Analyst Ratings Have To Say About Sangamo Therapeuticsmarkets.businessinsider.com - November 6 at 12:54 PMRBC Capital downgrades Sangamo as biotech moves to save cashmsn.com - November 3 at 7:45 PMRBC Capital Downgrades Sangamo Therapeutics (SGMO)msn.com - November 3 at 7:45 PMSangamo Therapeutics, Inc. (NASDAQ:SGMO) Q3 2023 Earnings Call Transcriptfinance.yahoo.com - November 3 at 7:45 PM Get Sangamo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SGMO and its competitors with MarketBeat's FREE daily newsletter. Email Address $21,000 in profits in six weeks? (Ad)On Wednesday, May 8, the legendary Jonathan Rose is holding his first ever Masters in Trading Summit. Jonathan is one of the sharpest traders I’ve ever met. He made millions trading in the pits of the world’s largest exchanges. Click here for details. SGMO Media Mentions By Week SGMO Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SGMO News Sentiment▼0.290.42▲Average Medical News Sentiment SGMO News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SGMO Articles This Week▼41▲SGMO Articles Average Week Get Sangamo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SGMO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CRIS News AGEN News SABS News ALVR News VIGL News PLX News ATRA News BLUE News OTLK News BCAB News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SGMO) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchCould Your Accounts Be Frozen?Allegiance GoldThe Gold Grab of the CenturyColonial MetalsStock-Picking AI Predicts #1 Stock of 2024AltimetryThe A.I. story nobody is telling you (Read ASAP)TradeSmithHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sangamo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
